SEC Form 4 · accession 0001209191-17-000996
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurence James Neil Cooper
Officer — Chief Executive Officer
Period of report
Dec 30, 2016
Accepted (ET)
Jan 4, 2017 · 4:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 30, 2016 | A | 212,250 | $0.00 | A | 1,226,583 | D | |
| Common StockF2 | Dec 31, 2016 | F | 17,292 | $5.35 | D | 1,209,291 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F170,750 shares vest on each of 12/30/2017, 12/30/2018 and 12/30/2019.
- F2Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.